Plain-English translation of NCT07101094 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →This trial is collecting information from adults with schizophrenia who are prescribed xanomeline and trospium chloride (a combination medication) to understand how satisfied they are with this treatment and how well it fits into their daily lives. Researchers want to learn about real-world experiences — not in a controlled lab setting, but in everyday life — so they can better understand whether this medication works well for people and meets their needs.
Schizophrenia is a serious mental health condition, and finding treatments that work well and that patients are happy to stick with is important. This study exists to gather feedback directly from people taking this new medication, so doctors and drug developers can understand what's working and what challenges patients face.
You likely qualify if…
You likely don't qualify if…
You would continue taking your new medication as prescribed by your doctor while participating in this registry study. Over time, you would share your experiences and feelings about the medication through electronic surveys or paper forms — answering questions about how satisfied you are, whether it's helping you, and how it fits into your life. The study is designed to fit into your normal routine rather than requiring frequent clinic visits.
AI-generated summary from trial data · Jun 22, 2026 · Not medical advice
United States